Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|May 11, 2012
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patientsVeronika Buxhofer-Ausch, Heinz Gisslinger, Jürgen Thiele, et al.
British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Heart (British Cardiac Society)|September 30, 2015
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortalityNoemi Pavo, Markus Raderer, Martin Hülsmann, et al.
Blood|January 17, 2012
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcomeTiziano Barbui, Jürgen Thiele, Francesco Passamonti, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.
Blood|August 11, 2020
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosisGeorg Greiner, Bettina Sprinzl, Aleksandra Górska, et al.
Therapeutic Advances in Hematology|September 15, 2022
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10<sup>9</sup>/L to <100 × 10<sup>9</sup>/L) at baseline: the final analysis of EXPANDPaola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.
Cancer Research|April 14, 2011
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosisChristophe Desterke, Chrystele Bilhou-Nabéra, Bernadette Guerton, et al.
British Journal of Haematology|March 29, 2019
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trialHeinz Gisslinger, Veronika Buxhofer-Ausch, Juri Hodisch, et al.
Pageof 15